tirzepatide cv outcomes Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

28.75

★★★★☆4.8 (126)

Tirzepatide linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s

25.05

★★★★★4.9 (98)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

24.50

★★★★★5.0 (157)

Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)

24.69

★★★★★4.7 (84)

SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening heart failure events and improved quality of life in patients with #HFpEF and obesity. “Cardiologists now have an ever-expanding

29.69

★★★★★4.9 (203)

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes @NEJM Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of

26.93

★★★★★5.0 (176)

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

29.80

★★★★★4.8 (132)